U.S. Surgical Sealants and Adhesives Market Size, Share & Forecast 2026–2032

ID: MR-11387 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Surgical Sealants and Adhesives Market
  • ✓Market Size 2024: USD 1.42 billion
  • ✓Market Size 2032: USD 2.36 billion
  • ✓CAGR: 6.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Plasma Sourcing Entry Barrier: Fibrin sealant share depends on upstream plasma access, where Baxter and CSL Behring control most U.S. fractionation capacity. Suppliers lacking secured plasma contracts cannot match incumbents' supply reliability in hospital tenders, making sourcing a stronger entry barrier than clinical data.
FINDING 02
Hybrid Portfolios Over Substitution: The assumption that synthetic adhesives will displace fibrin sealants overlooks surgeon reliance on biologic hemostats for vascular and neurosurgical work. Hybrid portfolios, not substitution, will shape share, favoring Johnson & Johnson and Baxter, which bundle both classes in hospital contracts.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Plasma and GPO Access: Mid-sized sealant suppliers should lock multi-year plasma supply agreements and secure at least one national group purchasing organization contract by year-end 2026. Both fibrin and synthetic portfolios depend on these access points, and QMSR alignment protects tender eligibility.

Competitive Overview: Surgical Sealants and Adhesives in the United States

The U.S. surgical sealants and adhesives market is moderately concentrated, with Johnson & Johnson's Ethicon franchise, Baxter International, and Artivion holding most hospital-grade fibrin and synthetic sealant volume. Domestic specialists such as Cohera Medical and Adhezion Biomedical compete in narrower indications, including cardiothoracic and pediatric procedures, where clinical differentiation matters more than scale. Advantage here rests on clinical evidence, surgeon training networks, and access to group purchasing organizations rather than manufacturing cost.

Multinationals capture the majority of revenue through value analysis committee approvals and integrated contracts that bundle sealants with staplers, hemostats, and robotic instruments. Surgeon preference is sticky: once a sealant is embedded in a surgical team's training, switching requires clinical re-education and new applicator workflows. Domestic firms lacking dedicated clinical specialists in operating rooms remain limited to single-site adoption, keeping national share concentrated among incumbents.

Demand Drivers Shaping U.S. Surgical Sealant and Adhesive Adoption

Robotic and minimally invasive surgery is the strongest near-term driver. Intuitive Surgical's da Vinci installed base across U.S. hospitals requires sealants delivered through compact applicators compatible with trocar-based access, a design advantage for Johnson & Johnson's Ethicon portfolio and Baxter's delivery systems. Applicator engineering, not formulation alone, now decides which brands capture new procedure volume in high-volume general and urologic programs.

Cardiovascular and orthopedic volumes are rising with an aging population, and Medicare reimbursement for complex cardiac and spinal procedures sustains demand for hemostatic sealants. Artivion benefits in aortic surgery, while Stryker and Integra LifeSciences compete in orthopedic and neurosurgical hemostasis. The migration of lower-acuity procedures into ambulatory surgery centers, supported by CMS expansions of the ASC covered procedures list, also opens channels for ready-to-use sealant kits.

Competitive Restraints Facing U.S. Sealant and Adhesive Suppliers

Price competition is intensifying as group purchasing organizations and integrated delivery networks consolidate sourcing. Value analysis committees increasingly request cost-per-procedure data, pressuring premium biologic sealants and compressing margins for smaller suppliers. Lower-cost alternatives, including conventional sutures and oxidized cellulose hemostats from large portfolios, cap sealant pricing in routine general surgery. Vendors competing on unit price rather than outcome evidence find themselves excluded from preferred-vendor lists.

Regulatory compliance costs and talent shortages constrain smaller competitors. Fibrin sealants require biologics licensing and plasma traceability, while synthetic products need premarket approval supplements for every labeling change, and Quality Management System Regulation alignment takes effect in February 2026. Infrastructure gaps, particularly plasma supply concentrated among a few fractionators, and a thin pool of experienced clinical sales specialists slow new entrants' hospital adoption.

Growth Opportunities for U.S. Sealant and Adhesive Players

Ambulatory surgery centers represent the largest untapped channel. Procedures migrating to outpatient settings need sealants packaged in single-use kits with simplified training, a model that smaller specialists such as Adhezion Biomedical can serve without matching large hospital sales forces. Suppliers securing ASC-specific pricing and distributor partnerships stand to gain share before the channel consolidates. Early contracts with regional ASC networks create switching costs that later entrants cannot easily break.

Neurosurgical and pediatric indications offer differentiated positioning. Dural sealing and cranial procedures have limited options and high clinical stakes, making them attractive for companies investing in targeted indication trials. Partnerships between medtech incumbents and academic medical centers, particularly in pediatric cardiac surgery, provide evidence generation that supports premium pricing and shortens hospital formulary approval cycles.

Market at a Glance

MetricValue
Market Size 2024USD 1.42 billion
Market Size 2032USD 2.36 billion
Growth Rate (CAGR)6.6%
Most Critical Decision FactorClinical evidence and GPO contract access
Largest RegionSouthern U.S. (Southeast and Texas)
Competitive StructureModerately concentrated; multinationals lead, domestic niche specialists

Leading Market Participants

  • Johnson & Johnson
  • Baxter International
  • Artivion
  • Medtronic
  • Stryker
  • Integra LifeSciences
  • B. Braun Melsungen
  • Cohera Medical
  • Adhezion Biomedical
  • Terumo Corporation

Regulatory and Policy Environment for U.S. Sealants and Adhesives

FDA oversight splits between two pathways. Fibrin sealants are licensed as biologics by the Center for Biologics Evaluation and Research, while synthetic polymer sealants such as BioGlue reach market through premarket approval under the Center for Devices and Radiological Health. MDUFA V performance goals set review timelines that shape launch sequencing, so competitive advantage depends on regulatory pathway expertise as much as formulation chemistry.

Reimbursement and transparency rules shape competitive behavior. Hospital price transparency requirements under 45 CFR Part 180 expose negotiated sealant prices, accelerating price discipline in tenders. The Physician Payments Sunshine Act, reported through CMS Open Payments, discloses manufacturer payments to surgeons and constrains how companies build training relationships. The Anti-Kickback Statute further limits how sales teams compensate surgeon advocates.

Competitive Outlook for U.S. Sealants and Adhesives by 2032

By 2032 the market will consolidate further around platform companies that combine sealants with stapling, hemostasis, and robotic delivery. Acquisitions of mid-sized specialists by strategic buyers will continue, transferring proprietary synthetic chemistries to portfolios with larger sales infrastructure. Johnson & Johnson, Baxter, Medtronic, and Stryker are best placed to absorb these assets, while independent players retaining clinical evidence in niche indications will remain viable.

Competitive intensity will shift from product differentiation to contract performance and cost-per-procedure proof. Synthetic sealants will gain share in ambulatory and robotic settings, while fibrin products hold their position in complex vascular and neurosurgical work. Firms that align QMSR compliance, plasma security, and evidence generation before 2030 will hold the strongest positions in the 2032 market.

Frequently Asked Questions

Johnson & Johnson, Baxter International, and Artivion hold the largest shares in hospital-grade sealants. Domestic specialists such as Cohera Medical and Adhezion Biomedical compete in narrower surgical niches.
GPO contracts determine which sealants reach hospital shelves and at what unit price. Vendors without national GPO agreements face limited adoption outside single health systems.
Yes, in indications where clinical evidence outweighs portfolio breadth, such as pediatric cardiac and neurosurgical procedures. Scale remains a constraint in general surgery, where multinationals bundle sealants with staplers and hemostats.
Secured human plasma supply for fibrin sealants and experienced clinical sales specialists are the most binding constraints. Regulatory pathway expertise across CBER and CDRH forms the second major barrier.
Platform players combining sealants with robotic-compatible delivery and stapling, including Johnson & Johnson, Medtronic, and Stryker, are best placed. Independent specialists with strong clinical evidence in niche indications will remain attractive acquisition targets.

Market Segmentation

By Product Type
  • Fibrin Sealants
  • Synthetic Adhesives
  • Collagen-Based Sealants
  • PEG-Based Sealants
  • Others
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Academic Medical Centers
By Application
  • Cardiovascular Surgery
  • General Surgery
  • Neurosurgery
  • Orthopedic Surgery

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Surgical Sealants and Adhesives - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Fibrin Sealants
4.2 Synthetic Adhesives
4.3 Collagen-Based Sealants
4.4 PEG-Based Sealants
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Specialty Clinics
5.4 Academic Medical Centers
5.5 Others
Chapter 06 Application Insights
6.1 Cardiovascular Surgery
6.2 General Surgery
6.3 Neurosurgery
6.4 Orthopedic Surgery
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Johnson & Johnson
7.2.2 Baxter International
7.2.3 Artivion
7.2.4 Medtronic
7.2.5 Stryker
7.2.6 Integra LifeSciences
7.2.7 B. Braun Melsungen
7.2.8 Cohera Medical
7.2.9 Adhezion Biomedical
7.2.10 Terumo Corporation
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.